E. Michael D. ("Mike") Scott is Executive VP / Executive Rebel with Vox Medica, Inc., an independent, Philadelphia-based, healthcare communications group of companies. He is also the current chairman of the National Organization for Rare Disorders (NORD).
Mr. Scott was born and educated in the UK, and has lived in the USA since 1985. He has spent some 40 years in the fields of scientific and medical communication, with specialized interests in areas from academic and educational publishing to advertising, public relations, public health, and advocacy. He is a member of the Board of Directors of NORD and of the International Myeloma Foundation, a co-founder of Prostate Cancer International, and a member or associate member of several professional organizations in the fields of oncology, hematology, urology, drug information, and medical writing. His primary professional interests today are in communications strategy, health care advocacy, and issues affecting the evolution of access to quality health care, with particular emphasis on cancer and rare disorders. He holds a BSc (Hons) in biochemistry from the University of Sussex.
According to data from a variety of sources, there are between 6,500 and 7,000 disorders that meet the criterion for definition as an “orphan disease” here in the USA: a prevalence of < 200,000 patients living with the particular disorder at any specific point in time. To date, the U.S. Food & Drug Administration (FDA) […]
Late on Tuesday evening this week, Senators Richard Burr (R, NC) and Tom Coburn (R, OK) quietly released the text of S.2292, the Promoting Accountability, Transparency, Innovation, Efficiency, and Timeliness at FDA Act of 2012 (the PATIENTS’ FDA Act), which they described in a media release as “a bill to help make sure that the […]
Enterprise EHR boosts scalability, interoperability, and governance for large healthcare systems.
An article by Chen et al., published recently in the journal Cell, offers us what Eric Topol has already dubbed “panor-omic” insight into a potential future — one in which our genomic data can be cross-correlated against other “omic” data (including transcriptomic, proteomic, metabolomic, and autoantibody profiles) to give individualized insights into our current clinical […]